듀레신구강용해필름0.2mg 효능·효과
광고
듀레신구강용해필름0.2mg 복용법 (용법·용량)
듀레신구강용해필름0.2mg 부작용·주의사항
전체 8개 항목 펼치기/접기
1. 경고
2. 다음 환자에는 투여하지 말 것.
3. 다음 환자에는 신중히 투여할 것.
4. 이상반응
5. 일반적주의
6. 상호작용
7. 임부 및 수유부에 대한 투여
8. 과량투여시의 처치
듀레신구강용해필름0.2mg 성분·함량
이 약 1매 (84.66mg, 37 X 27mm, 70um) 중 기준
| 성분 | 영문 | 분량 |
|---|---|---|
| 데스모프레신아세트산염 | Desmopressin Acetate | 0.20 밀리그램 |
듀레신구강용해필름0.2mg 낱알 모양 (식별 표시)
- 모양
- 사각형 · 구강붕해필름
- 색
- 분홍
- 표시(앞/뒤)
- - / -
- 크기
- 37 × 27 mm, 두께 0.1mm
📍 듀레신구강용해필름0.2mg 살 수 있는 내 주변 약국
전문의약품은 의사 처방전이 있어야 약국에서 받을 수 있습니다. 재고는 약국에 전화로 확인하세요.
🗺️ 지도에서 찾기🌐 해외(미국) 정보 — 데스모프레신아세트산염
미국 FDA·NLM 자료 · 2026-10-01 기준이 성분은 한국어 번역이 없습니다(검수 전 자동 번역 게시는 멈춰 두었습니다). 아래는 미국 FDA 원문입니다 — 원문 라벨(DailyMed).
미국에서 쓰이는 곳(적응증)
영어 원문 (미국 FDA 라벨)
Desmopressin acetate injection is a vasopressin analog used for: Central Diabetes Insipidus - as antidiuretic replacement therapy in the management of central (cranial) diabetes insipidus and for the management of the temporary polyuria and polydipsia following head trauma or surgery in the pituitary region. ( 1.1 ) Hemophilia A- for patients with factor VIII coagulant activity levels greater than 5% to maintain hemostasis during surgical procedures and postoperatively or reduce bleeding with episodes of spontaneous or traumatic injuries such as hemarthroses, intramuscular hematomas, or mucosal bleeding. ( 1.2 ) von Willebrand’s disease (Type I) - for patients with mild to moderate disease with factor VIII levels greater than 5% to maintain hemostasis during surgical procedures or traumatic injuries such as hemarthroses, intramuscular hematomas, or mucosal bleeding. ( 1.3 ) Limitations of Use Desmopressin acetate is ineffective and not indicated for the treatment of nephrogenic diabetes insipidus. ( 1.3 ) von Willebrand’s disease (severe Type I) - not indicated for the treatment of patients with severe Type I von Willebrand’s disease and when there is evidence of an abnormal molecular form of factor VIII antigen. ( 1.3 ) 1.1 Central Diabetes Insipidus Desmopressin acetate injection is indicated as antidiuretic replacement therapy in the management of central (cranial) diabetes insipidus and for the management of the temporary polyuria and polydipsia following head trauma or …
⚠️ 박스 경고(가장 강한 경고)
영어 원문 (미국 FDA 라벨)
WARNING: HYPONATREMIA Desmopressin acetate can cause hyponatremia. Severe hyponatremia can be life-threatening, leading to seizures, coma, respiratory arrest, or death [see Warnings and Precautions ( 5.1 )] . Desmopressin acetate is contraindicated in patients at increased risk of severe hyponatremia, such as patients with excessive fluid intake, illnesses that can cause fluid or electrolyte imbalances, and in those using loop diuretics or systemic or inhaled glucocorticoids [see Contraindications ( 4 ) and Warnings and Precautions ( 5.1 )]. Ensure the serum sodium concentration is normal before starting or resuming desmopressin acetate. Measure serum sodium within 7 days and approximately 1 month after initiating therapy, and periodically during treatment. More frequently monitor serum sodium in patients 65 years of age and older and in patients at increased risk of hyponatremia [see Dosage and Administration ( 2.1 ) and Warnings and Precautions ( 5.1 )]. If hyponatremia occurs, desmopressin acetate may need to be temporarily or permanently discontinued [see Warnings and Precautions ( 5.1 )]. WARNING: HYPONATREMIA See full prescribing information for complete boxed warning. Desmopressin acetate can cause hyponatremia, which may be life-threatening if severe. ( 5.1 ) Desmopressin acetate is contraindicated in patients at increased risk of severe hyponatremia, such as patients with excessive fluid intake, illnesses that can cause fluid or electrolyte imbalances, and in those …
쓰면 안 되는 경우
영어 원문 (미국 FDA 라벨)
Desmopressin acetate injection is contraindicated in patients with known hypersensitivity to desmopressin acetate or to any of the components of desmopressin acetate injection [see Warnings and Precautions ( 5.4 ), Adverse Reactions ( 6 ), Description ( 11 )] . Desmopressin acetate injection is contraindicated in patients with the following conditions due to an increased risk of hyponatremia: Moderate to severe renal impairment defined as a creatinine clearance below 50 mL/min [see Use in Specific Populations ( 8.5 , 8.6 ) and Clinical Pharmacology ( 12.3 )]. Hyponatremia or a history of hyponatremia [see Warnings and Precautions ( 5.1 ), Drug Interactions ( 7.1 ), Use in Specific Populations ( 8.4 , 8.5 )] . Known or suspected syndrome of inappropriate antidiuretic hormone (SIADH) secretion [see Warnings and Precautions ( 5.1 )] . Polydipsia [see Warnings and Precautions ( 5.1 )]. Concomitant use with loop diuretics [see Boxed Warning ] . Concomitant use with systemic or inhaled …
주요 경고·주의
영어 원문 (미국 FDA 라벨)
Hypotension and Hypertension: May cause hypotension with compensatory increase in heart rate or hypertension. Monitor blood pressure during desmopressin acetate administration, especially in patients with heart disease. ( 5.2 ) Increased Risk of Thrombosis in Patients with von Willebrand’s Disease Type IIB: Use of desmopressin acetate in patients with Type IIB von Willebrand’s disease may cause thrombosis due to platelet aggregation. ( 5.3 ) Hypersensitivity Reactions: Severe reactions have occurred. Monitor for reactions during administration and interrupt if reaction occurs. ( 5.4 ) Fluid Retention: Fluid retention can worsen underlying conditions that are susceptible to volume status. Not recommended in patients at risk for increased intracranial pressure or with a history of urinary retention. ( 5.5 ) 5.1 Hyponatremia Desmopressin acetate injection can cause hyponatremia. Severe hyponatremia can be life-threatening if it is not promptly diagnosed and treated, leading to seizures, coma, respiratory arrest, or death [see Boxed Warning ]. Desmopressin acetate injection is contraindicated in patients with hyponatremia (or a history of hyponatremia), with excessive fluid intake (e.g., polydipsia), using loop diuretics or systemic or inhaled glucocorticoids, with known or suspected SIADH, and/or illnesses that can cause fluid or electrolyte imbalances [see Contraindications ( 4 ), Drug Interactions ( 7 )] . Avoid concomitant treatments that also cause hyponatremia. Prior to …
임신·특수 환자
영어 원문 (미국 FDA 라벨)
Pediatric Use: Initiate fluid intake restriction to prevent possible hyponatremia and water intoxication. ( 8.4 ) Geriatric Use: Carefully select dose and monitor renal function more frequently. ( 8.5 ) See 17 for PATIENT COUNSELING INFORMATION. 8.1 Pregnancy Risk Summary Prolonged experience with desmopressin acetate injection in pregnant women over several decades, based on the available published literature and case reports, have not identified a drug associated risk of major birth defects, miscarriage or other adverse maternal or fetal outcomes. In addition, in vitro studies with human placenta demonstrate poor placental transfer of desmopressin. No adverse developmental outcomes were …
미국 제품명 DDAVP, DESMODA
미국 부작용 보고(FAERS)에 많이 나온 증상
미국 FDA에 접수된 이 성분 관련 보고 3,776건 가운데 많이 적힌 증상입니다. 보고 수는 약 때문이라는 증거가 아니며, 많이 쓰는 약일수록 많아집니다. 증상 이름의 한국어는 AI 번역(참고용)이라 영어 원어를 함께 적었습니다.
- 1 HYPONATRAEMIA357
- 2 두통headache268
- 3 약효 없음drug ineffective258
- 4 오심nausea204
- 5 피로fatigue173
- 6 구토vomiting154
- 7 적응증 외 사용off label use146
- 8 어지러움dizziness138
- 9 설사diarrhoea116
- 10 통증pain115
- 11 쇠약asthenia100
- 12 코피epistaxis99
미국 리콜 기록
FDA 리콜(회수) 기록 1건 중 최근 1건 — 특정 회사·제조번호 제품의 회수로, 국내 제품과는 관계없을 수 있습니다.
- 2022.12.07 · 2등급 · Heritage Pharmaceuticals Inc Subpotent Drug
출처: 미국 FDA openFDA(라벨·FAERS·리콜), 미국 국립의학도서관 RxNorm · DailyMed 원문 라벨. 한국어는 오픈드럭 서버 AI(gemma)가 자동 번역한 참고용(사람 검수 전)으로 오역이 있을 수 있으니 반드시 원문을 확인하세요.
허가 정보
- 품목기준코드
- 201600439
- 허가 구분
- 허가 · 완제의약품
- 상태
- 정상
- 저장 방법
- 기밀용기, 실온(1~30℃)보관
- 사용 기간
- 제조일로부터 36 개월
- 포장 단위
- 15매(1매/알루미늄 호일 포장 X15)
- ATC 코드
- H01BA02
- 보험 코드
- 669501390
- 표준코드
- 8806695013903, 8806695013910, 8806695013927, 8806695013934
- 최근 변경
- 2025.12.26
허가 변경 이력
- · 사용상주의사항변경(부작용포함), 2025-12-26
- · 사용상주의사항변경(부작용포함), 2024-05-28
원문: 식약처 의약품안전나라
같은 성분의 다른 제품
이텍스데스모프레신정0.2밀리그램(데스모프레신아세트산염) (주)테라젠이텍스· 뇌하수체호르몬제· 2022년 허가 전문 이텍스데스모프레신정0.1밀리그램(데스모프레신아세트산염) (주)테라젠이텍스· 뇌하수체호르몬제· 2021년 허가 전문
미니페정0.2밀리그램(데스모프레신아세트산염) 대웅바이오(주)· 뇌하수체호르몬제· 2019년 허가 전문
미니페정0.1밀리그램(데스모프레신아세트산염) 대웅바이오(주)· 뇌하수체호르몬제· 2019년 허가 전문 미니스정0.2밀리그램(데스모프레신아세트산염) (주)이든파마· 뇌하수체호르몬제· 2019년 허가 전문 미니스정0.1밀리그램(데스모프레신아세트산염) (주)이든파마· 뇌하수체호르몬제· 2019년 허가 전문 모나린정0.1밀리그램(데스모프레신아세트산염) 아주약품(주)· 뇌하수체호르몬제· 2019년 허가 전문
뉴리탄정0.1밀리그램(데스모프레신아세트산염) (주)넥스팜코리아· 뇌하수체호르몬제· 2018년 허가 전문
녹더나설하정25마이크로그램(데스모프레신아세트산염) 한국페링제약(주)· 뇌하수체호르몬제· 2017년 허가 전문
녹더나설하정50마이크로그램(데스모프레신아세트산염) 한국페링제약(주)· 뇌하수체호르몬제· 2017년 허가 전문
뉴리탄정0.2밀리그램(데스모프레신아세트산염) (주)넥스팜코리아· 뇌하수체호르몬제· 2017년 허가 전문
미니모프레신정0.1mg(데스모프레신아세트산염) 한국휴텍스제약(주)· 뇌하수체호르몬제· 2016년 허가 전문